Product Images Sacubitril And Valsartan

This is a description of a unit dose of Sacubitril and Valsartan tablets containing 24 mg of sacubitril monosodium and 26 mg of valsartan disodium, with each tablet equivalent to 26 mg of sacubitril and 28.3 mg of valsartan. The package contains 30 tablets and should be stored at temperatures ranging from 20°C to 25°C (68°F to 77°F), with limited excursions between 5°C to 30°C (41°F to 86°F). It is important to protect the tablets from moisture and keep them out of reach of children. Please see prescribing information for usual dosage.*

This text appears to be a description of a medication called Sacubitril and Valsartan, presented in tablets form with a dosage of 49 mg of Sacubitril and 51 mg of Valsartan. The medication is packaged in 30 tablets in a unit dose format, meaning it is divided into individual doses. The recommended storage conditions are between 15°C to 25°C (59°F to 77°F) to protect from moisture. The text also includes information about the controlled room temperature and advising to keep the medication out of reach of children. The medication is intended for prescription use only.*

Description: This text provides information about a unit dose pack of Sacubitril and Valsartan tablets. It includes details about the product code, dosage, storage instructions, manufacturer, and distributor. The medication is intended for prescription use only and the usual dosage guidance is recommended to be followed. The text also mentions the temperature range for storage and protection from moisture. The product is manufactured by Alkom Laboratories Ltd. in Mumbai, India, and distributed by Major Pharmaceuticals in Indianapolis, USA.*

The text shows a Figure A illustrating the Time to First Occurrence of Cardiovascular (CV) Death or Heart Failure Hospitalizations in the PARADIGM-HF trial. The data includes p-values, Hazard Ratios (HR) with 95% Confidence Intervals, and compares Sacubitril and Valsartan with Enalapril over time since randomization in days. The results indicate statistical significance (p<0.0001) in favor of Sacubitril and Valsartan with a lower HR compared to Enalapril.*

The text provides information on the Time to Occurrence of CV Death in the PARADIGM-HF study. It presents data on Hazard Ratio (HR) with a confidence interval, as well as the number of patients at risk over different time intervals since randomization. The study appears to compare Sacubitril and Valsartan with Enalapril in relation to cardiovascular outcomes.*

This text provides information on the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF trial. The data includes hazard ratios with corresponding confidence intervals comparing Sacubitril and Valsartan to Enalapril. It also presents the number of patients at risk over time since randomization in days.*

This document appears to be a summary showing various subgroups within a population and their corresponding percentages for different parameters such as age, gender, weight, race, comorbidities like diabetes and hypertension, blood pressure levels, presence of atrial fibrillation, prior medication use, heart failure hospitalization, and cause of heart failure. Additionally, it looks at factors like estimated GFR, systolic blood pressure levels, and time since the diagnosis of heart failure. This data seems to be related to the evaluation of Sacubitril and Valsartan compared to Enalapril in the context of heart failure treatment.*

This is a list of coadministered drugs along with specific details such as Geometric Mean Ratio and 90% Confidence Interval. These drugs include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The information provided likely relates to the pharmacokinetics or drug interactions of these medications when taken together.*